Rhabdomyolysis caused by a potential sitagliptin-lovastatin interaction

Pharmacotherapy

Volumn 29, Issue 3, 2009, Pages 352-356

  Digregorio, Robert V ^a,b   Pasikhova, Yanina ^b  

^a LONG ISLAND UNIVERSITY   (United States)

^b BROOKLYN HOSPITAL CENTER   (United States)

Author keywords

Drug drug interaction; Lovastatin; Rhabdomyolysis; Sitagliptin

Indexed keywords

ALENDRONIC ACID; CREATINE KINASE ISOENZYME; CYANOCOBALAMIN; CYTOCHROME P450 3A4; DEXTROPROPOXYPHENE; DILTIAZEM; ESOMEPRAZOLE; FOLIC ACID; GLIMEPIRIDE; HYDROCHLOROTHIAZIDE; HYDROMORPHONE; LEVOTHYROXINE; METHOCARBAMOL; METOCLOPRAMIDE; MEVINOLIN; PARACETAMOL; PIOGLITAZONE; PYRIDOXINE; ROSIGLITAZONE; SITAGLIPTIN; TIOTROPIUM BROMIDE;

AGED; ARTICLE; BACKACHE; BEDTIME DOSAGE; BLOOD CELL COUNT; CASE REPORT; CONSULTATION; DIABETES CONTROL; DIABETES MELLITUS; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LABORATORY TEST; LIMB WEAKNESS; PENICILLIN ALLERGY; RHABDOMYOLYSIS; THORAX RADIOGRAPHY; VITAL SIGN;

AGED; ANTICHOLESTEREMIC AGENTS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LOVASTATIN; PYRAZINES; RHABDOMYOLYSIS; TRIAZOLES;

EID: 62549110786     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.29.3.352     Document Type: Article

References (19)

1. Choy M, Sum L. Sitagliptin a novel drug for the treatment of type 2 diabetes. Cardiol Rev 2007;15:264-71.
2. American Diabetes Association. Standard of medical care in diabetes. Diabetes Care 2007;30:S4-41.
3. National Cholesterol Education Program, National Heart, Lung and Blood Institute, National Institutes of Health. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (adult treatment panel III): final report. NIH publication no. 02-5215. September 2002. Available from www.nhlbi.nih.gov/guidelines/cholesterol/atp3full.pdf. Accessed November 10, 2007.
4. Drucker D, Easley C, Kirkpatrick P. Sitagliptin. Nat Rev Drug Discov 2007;6:109-10.
5. Merck & Co., Inc. Januvia (sitagliptin) package insert. Whitehouse Station, NJ; 2007.
6. Merck & Co., Inc. Mevacor (lovastatin) package insert. Whitehouse Station, NJ; 2007.
7. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006;80:565-81.
8. Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 2001;35:1096-106.
9. Jois-Bilowich P, LeBlanc H, Paula R. Rhabdomyolysis: diagnosis and treatment [online exclusive article]. Resident Staff Physician 2007; 56(6). Available from www.residentandstaff.com/issues/articles/2007-06-03.asp. Accessed October 28, 2007.
10. Brown TP. Exertional rhabdomyolysis. Phys Sportsmed 2004;32:15-20.
11. Wratchford P, Ponte C D. High-dose simvastatin and rhabdomyolysis. Am J Health Syst Pharm 2003;60(7):698-700.
12. Horn JR, Hansten PD, Chan L. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother 2007;41:674-80.
13. Gladding P, Edwards C. Potentially fatal interaction between diltiazem and statins [letter]. Ann Intern Med 2004;140:W31.
14. Prall AJ, Breeze RE. Rhabdomyolysis following spinal cord injury: case report. J Trauma 1995;39:802-4.
15. Kisakol G, Kaya A. Rhabdomyolysis in a patient with hypothyroidism. Endocr J 2003;50:221-3.
16. Altay M, Duranay M, Ceri M. Rhabdomyolysis due to hypothyroidism. Nephrol Dial Transpl 2005;20:847-8.
17. Kiernab TJ, Rochford M, McDermott JH. Simvastatin induced rhabdomyolysis and an important clinical link with hypothyroidism. Int J Cardiol 2007;119:374-6.
18. Wang AA, Hutchinson DT. The effect of corticosteroid injections for trigger finger on blood glucose level in diabetic patients. J Hand Surg [Am] 2006;31A:979-81.
19. Hansen KE, Hildebrand JP, Ferguson EE, Stein JH. Outcome in 45 patients with statin-associated myopathy. Arch Intern Med 2005;165:2671-6.